Sign In
Buy APTO
$1.71
+0 (+0%)
At Close: Jul 25, 2025
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
07:30am, Friday, 14'th Jun 2024
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from oth
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
01:21pm, Thursday, 13'th Jun 2024
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:30pm, Monday, 03'rd Jun 2024
SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hi
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Friday, 31'st May 2024
SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing hig
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript
11:12pm, Tuesday, 14'th May 2024
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Susan Pietropaolo - MD, Corporate Communications and IR William Rice - Chairman, Pr
Aptose Reports Results for the First Quarter 2024
04:01pm, Tuesday, 14'th May 2024
TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AM
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
04:30pm, Monday, 06'th May 2024
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted ag
What Makes Aptose Biosciences (APTO) a New Buy Stock
01:01pm, Friday, 05'th Apr 2024
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
08:38pm, Tuesday, 26'th Mar 2024
Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript
Aptose Reports Results for the Fourth Quarter and Full Year 2023
04:01pm, Tuesday, 26'th Mar 2024
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML Tuspetinib Continues Broad Activity Across Mutations with Excellent Safety Profile Luxeptinib G3 Formulation Achieves Desired
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
04:30pm, Monday, 18'th Mar 2024
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted
SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing
Why Is Aptose Biosciences (APTO) Stock Down Today?
08:36am, Friday, 26'th Jan 2024
Aptose Biosciences (NASDAQ: APTO ) stock is on the move Friday after announcing details for a public offering of the clinical-stage biotechnology company's shares. Aptose Biosciences is selling 4,912
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
08:00am, Friday, 26'th Jan 2024
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing h
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
06:30pm, Saturday, 09'th Dec 2023
Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Fa
